Linaclotide

• UNSPSC Description:

  Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

• Target Antigen:

  Guanylate Cyclase

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Linaclotide.html

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)|H2O : 16.67 mg/mL (ultrasonic;adjust pH to 2 with HCl)

• Smiles:

  O=C([C@@H](NC([C@@](CSSC[C@@H]1N)([H])NC([C@@](CSSC[C@H](N2)C(N[C@H](C(O)=O)CC3=CC=C(O)C=C3)=O)([H])NC([C@@H](NC([C@@H](N4)CCC(O)=O)=O)CC5=CC=C(O)C=C5)=O)=O)=O)CC(N)=O)N6[C@@](C(N[C@H](C(N[C@](CSSC[C@](C4=O)([H])NC1=O)([H])C(NC(C(NCC2=O)=O)[C@H](O)C)=O)=O)C)=O)([H])CCC6

• Molecular Weight:

  1526.74

• References & Citations:

  [1]Bryant AP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010 May 8;86(19-20):760-5.|[2]Love BL, et al. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome. Am J Health Syst Pharm. 2014 Jul 1;71(13):1081-91.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  Launched

• CAS Number:

  851199-59-2